 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| UCLM802 / UTC Therap
New P1 trial, CAR T-Cell Therapy, Metastases: UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - May 8, 2023
P1, N=87, Recruiting, Sponsor: Zhejiang University
- ||| UCLM802 / UTC Therap
New P1 trial, CAR T-Cell Therapy, Metastases: MSLN-targeted CAR-T Cells in Solid Tumors. (clinicaltrials.gov) - Mar 24, 2023
P1, N=87, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||| UCLM802 / UTC Therap
New P1 trial, CAR T-Cell Therapy, Metastases: UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - Mar 20, 2023
P1, N=87, Not yet recruiting, Sponsor: Peking University
- | UCLM802 / UTC Therap
Enrollment change, Trial withdrawal, CAR T-Cell Therapy, Metastases: Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov) - Mar 1, 2023
P1, N=0, Withdrawn, Sponsor: Shanghai Pudong Hospital
N=20 --> 0 | Recruiting --> Withdrawn
- || UCLM802 / UTC Therap
New P1 trial, CAR T-Cell Therapy, Metastases: Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov) - Sep 8, 2022
P1, N=20, Recruiting, Sponsor: Shanghai Pudong Hospital
- | UCLM802 / UTC Therap
New P1 trial, CAR T-Cell Therapy, Metastases: Amaretto: Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Jul 28, 2021
P1, N=12, Recruiting, Sponsor: Ruijin Hospital